Search for a clinical trial
Other search option(s)
14 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
CZECH REPUBLIC
Capital City Prague
ADDRESS: NOT PROVIDED - CZ
ARISE (LAL-CL02): A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency (Phase III) - CZ
Institution: Information not provided - CZ
FRANCE
GRAND-EST
VANDOEUVRE-LÈS-NANCY
ARISE: A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency (Phase III) - FR
CHU de Nancy - Hôpitaux de Brabois
Service de médecine infantile
FRANCE
ILE-DE-FRANCE
PARIS
ARISE: A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency (Phase III) - FR
Hôpital Necker-Enfants Malades
Service des Maladies Métaboliques pédiatriques
FRANCE
ILE-DE-FRANCE
PARIS
LAL-CL04: An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01 (Phase II) - FR
Hôpital Necker-Enfants Malades
Service des Maladies Métaboliques pédiatriques
GREECE
GREECE
ADDRESS: NOT PROVIDED - GR
ARISE (LAL-CL02): A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency (Phase III) - GR
Institution: Information not provided - GR
NETHERLANDS
Noord-Holland
AMSTERDAM
A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency (Phase II) - NL
Amsterdam UMC, locatie AMC
Polikliniek Kindermetabole Ziekten
POLAND
Kraków
ADDRESS: NOT PROVIDED - PL
ARISE (LAL-CL02): A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency (Phase III) - PL
Institution: Information not provided - PL
UNITED KINGDOM
Greater Manchester
SALFORD
LAL-CL04: An open label multicenter extension study to evaluate the long-term safety, tolerability, and efficacy of SBC-102 in adult subjects with liver dysfunction due to lysosomal acid lipase deficiency who previously received treatment in study LAL-CL01 (Phase II) - UK
Salford Royal NHS Foundation Trust
UNITED KINGDOM
West Midlands
BIRMINGHAM
ARISE (LAL-CL02): A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency (Phase III) - UK
University of Birmingham
University of Birmingham HQ
UNITED STATES
Connecticut
CHESHIRE
ARISE: A phase 3 multicenter, randomized, placebo-controlled study of SBC-102 in patients with Lysosomal Acid Lipase Deficiency - DE
Alexion Pharmaceuticals, Inc.
UNITED STATES
Connecticut
CHESHIRE
A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency (Phase II) - DE
Alexion Pharmaceuticals, Inc.
UNITED STATES
Massachusetts
LEXINGTON
ARISE: A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency - CA
Synageva BioPharma Corp
Multinational clinical trial(s)
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK
LAL-CL01: An Open Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Patients With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency (Phase I)
Institution: Information not provided - UK
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK